NSEPress Release23h ago · 18 Nov 2026, 08:34 am
Press Release
Biocon Limited · BIOCON
✦ AI Summary▲ PositiveRegulatory
Biocon Limited has announced that the European Commission has granted marketing authorization for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This milestone follows its positive CHMP opinion on September 17, 2026.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment9/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Biocon Limited has informed the Exchange regarding a press release dated November 18, 2026, titled "Biocon s Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach".
Attachments (1)
📄pdf
Download →
BIOCON_18112026083410_Pressrelease18112026.pdf
View document text
Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417
E: co.secretary@biocon.com
www.biocon.com
BIO/SECL/TG/2026-27/88
November 18, 2026
To To
The Manager, The Manager,
BSE Limited National Stock Exchange of India Limited
Department of Corporate Services Corporate Communication Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001 Mumbai – 400 051
Scrip Code - 532523 Scrip Symbol - BIOCON
Dear Sir/ Madam,
Subject: Press Release
Please find enclosed the press release titled “Biocon’s Pertuzumab Gets Marketing Authorization in
EU, First Biosimilar Approved Under New Tailored Clinical Approach”.
The above information will also be available on the website of the Company at www.biocon.com.
Kindly take the same on record and acknowledge.
Thanking You,
Yours faithfully,
For Biocon Limited
Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328
Encl: Press Release
PRESS RELEASE
Biocon’s Pertuzumab Gets Marketing Authorization in EU,
First Biosimilar Approved Under New Tailored Clinical Approach
• EC approval follows recent U.S. FDA approval for the biosimilar
• Aims to broaden treatment options for patients with HER2-positive breast cancer while
supporting more sustainable healthcare systems in Europe
• The milestone further strengthens Biocon’s growing oncology portfolio and its focus on
addressing evolving patient and healthcare needs
Bengaluru, Karnataka, India, November 18, 2026
Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation-led global biopharmaceutical company,
today announced that the European Commission (EC) has granted marketing authorization for
Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple
disease stages in the European Union (EU).
Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the
European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive
CHMP opinion on September 17, 2026.
Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of
Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a
significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology
biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio
and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for
patients with HER2-positive breast cancer.”
Molecule Information:
Biocon’s pertuzumab biosimilar, approved as a 420 mg concentrate for solution for infusion, is a
biosimilar medicinal product and the active substance is pertuzumab, a monoclonal antibody that
binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2),
inhibiting the proliferation of tumour cells that overexpress HER2.
Biocon’s pertuzumab biosimilar is indicated for use in combination with trastuzumab and
chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced,
inflammatory, or early-stage breast cancer at high risk of recurrence, as well as in the adjuvant
treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
In addition, it is indicated for use in combination with trastuzumab and docetaxel in adult patients with
HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received
previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Extensive orthogonal, state-of-the-art structural and functional analytical characterisation, together
with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is
highly similar to the reference product, with no clinically meaningful differences in quality, safety, or
efficacy.
Biocon in Oncology
Biocon has a strong and growing commitment to oncology, with a portfolio spanning multiple areas of
cancer care, including solid tumors such as breast cancer, as well as supportive care addressing
chemotherapy-induced neutropenia. This commitment also extends to bone health, with therapies
addressing osteoporosis, treatment-related bone loss and skeletal complications associated with
advanced cancers1. Biosimilar pertuzumab further strengthens the company’s portfolio and its ability
to support patients across different stages of the cancer care journey and diverse healthcare systems.
Epidemiology:
Breast cancer remains the most commonly diagnosed cancer among women in Europe. According to
2024 estimates from the European Cancer Information System (ECIS), it is the leading cancer diagnosis
among women across Europe2. Approximately 15–20% of invasive breast cancers are characterised by
HER2 overexpression or amplification3.Despite significant advances in HER2-targeted treatment, the
burden of breast cancer underscores the importance of broad and sustainable access to high-quality
treatment options across European healthcare systems.2,3
About Biocon Limited
Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide
affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some
of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both
biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high
unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology,
ophthalmology, and bone health. The company has pioneered several industry firsts that have helped shape the global
biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations
globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other
complex generics. With an integrated lab-to-patient model, Biocon brings together research and development,
manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates
in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a
workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the
fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website:
www.biocon.com Follow us on X: @bioconlimited LinkedIn: Biocon
Note: All trademarks, registered or unregistered, are the property of their respective owners.
FOR MORE INFORMATION
For Media For Investors
Rumman Ahmed Prashant Nair
Head – External Communications, Biocon Head – Investor Relations, Biocon
+91 98451 04173 +91 98200 95476
rumman.ahmed@biocon.com Prashant.nair@biocon.com
Gabriella Papale
Communications Lead Europe, Biocon
gabriella.papale@biocon.com
1 Li K, Qian Y, Cao Y. Risk of osteoporosis and fracture among patients with breast cancer: a systematic review and meta-
analysis of cohort studies. Front Oncol. 2026 Aug 31;16:1905334. https://pmc.ncbi.nlm.nih.gov/articles/PMC13572274/
2 European Cancer Information System (ECIS), European Commission Joint Research Centre. Female Breast Cancer in EU-
27/EFTA Countries: Estimates for 2024. October 2026
https://ecis.jrc.ec.europa.eu/sites/default/files/2026-10/2026-10_A4_Factsheet_breast-cancer_F.pdf
3 Marra A. et al. Management of advanced-stage HER2+ breast cancer: current evidence and future perspectives. Nature
Reviews Clinical Oncology. 2024;21:185–202. The review reports HER2 overexpression or amplification in approximately 15–
20% of invasive breast cancers
https://pmc.ncbi.nlm.nih.gov/articles/PMC12327481/